FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1% Sterile

Manufacturer
Eyevance Pharmaceuticals | Alcon Research LLC | Sicor Societa' Italiana Corticosteroidi s.r.l
Effective date
2025-01-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
full-release
Hydrated at
2026-05-31 21:23:01

Label at a glance#

ProductFlarex
Active ingredientFLUOROMETHOLONE ACETATE
Label structure12 sections

Indications and uses

FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Dosage and administration

Shake Well Before Using. One to two drops instilled into the conjunctival sac(s) four times daily. During the initial 24 to 48 hours the dosage may be safely increased to two drops every two hours. If no improvement after two weeks, consult physician. Care should be taken not to discontinue therapy prematurely. Not more than one bottle should be prescribed initially, and the prescription should not be refilled wit...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1% is a corticosteroid prepared as a sterile topical ophthalmic suspension. The active ingredient, fluorometholone acetate, is a white to creamy white powder with an empirical formula of C 24H 31FO 5 and a molecular weight of 418.5. Its chemical name is 9-fluoro-11β, 17-dihydroxy-6α-methylpregna-1, 4-diene-3, 20-dione 17-acetate. The chemical structure of Fluorometholone Acetate is presented below:

Chemical StructureChemical Structure

Each mL of FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% contains: Active: fluorometholone acetate 1 mg (0.1%). Preservative: benzalkonium chloride 0.01%. Inactives: sodium chloride, monobasic sodium phosphate, edetate disodium, hydroxyethyl cellulose, tyloxapol, hydrochloric acid and/or sodium hydroxide (to adjust pH), and purified water. The pH of the suspension is approximately 7.3, with an osmolality of approximately 300 mOsm/kg.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Corticosteroids suppress the inflammatory response to inciting agents of mechanical, chemical or immunological nature. No generally accepted explanation of this steroid property has been advanced. Corticosteroids cause a rise in intraocular pressure (IOP) in susceptible individuals. In a small study, FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% demonstrated a significantly longer average time to produce a rise in IOP than did dexamethasone phosphate; however, the ultimate magnitude of the rise was equivalent for both drugs and in a small percentage of individuals a significant rise in IOP occurred within three days.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Contraindicated in acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons who have known hypersensitivity to any component of this preparation.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION. Use in the treatment of herpes simplex infection requires great caution. Prolonged use may result in glaucoma, damage to the optic nerve, defect in visual acuity and visual field, cataract formation and/or may aid in the establishment of secondary ocular infections from pathogens due to suppression of host response. Acute purulent infections of the eye may be masked or exacerbated by presence of steroid medication. Topical ophthalmic corticosteroids may slow corneal wound healing. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with chronic use of topical steroids. If these products are used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.

Prescription Guidelines

SPL UNCLASSIFIED SECTION

The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the suspension. The preservative in FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% but may be reinserted 15 minutes after instillation.

Patients should be advised that their vision may be temporarily blurred following dosing with FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%. Care should be exercised in operating machinery or driving a motor vehicle.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been conducted in animals or in humans to evaluate the possibility of these effects with fluorometholone.

Pregnancy

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida were observed. There are no adequate and well controlled studies of fluorometholone in pregnant women, and it is not known whether fluorometholone can cause fetal harm when administered to a pregnant woman. Fluorometholone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur.

Postmarketing Experience

POSTMARKETING EXPERIENCE SECTION

The following reaction has been identified during post-marketing use of FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1% in clinical practice. Because reactions are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reaction, which has been chosen for inclusion due to either its seriousness, frequency of reporting, possible causal connection to FLAREX, or a combination of these factors, includes: dysgeusia.

The following rare adverse reactions have been reported: Cushing's syndrome and adrenal suppression may occur after very frequent use of topical ophthalmic corticosteroids, particularly in very young children.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Shake Well Before Using. One to two drops instilled into the conjunctival sac(s) four times daily. During the initial 24 to 48 hours the dosage may be safely increased to two drops every two hours. If no improvement after two weeks, consult physician. Care should be taken not to discontinue therapy prematurely.

Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation [see PRECAUTIONS] .

HOW SUPPLIED

HOW SUPPLIED SECTION

FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is supplied in white low density polyethylene (LDPE) bottles, with natural LDPE dispensing plugs and pink polypropylene closures. The product is supplied as 5 mL in an 8 mL bottle.

5 mL:NDC 71776-100-05

STORAGE

STORAGE AND HANDLING SECTION

Store upright between 2°C to 25°C (36°F to 77°F). After opening, FLAREX can be used until the expiration date on the bottle.

Protect from freezing.

SPL UNCLASSIFIED SECTION

Manufactured for:
Eyevance Pharmaceuticals, LLC
Fort Worth, TX 76102 USA
Revised: 7/2022

PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

2.5 mL2.5 mLSample - Not for Sale

eyevance ®

pharmaceuticals

Flarex ®

(fluorometholone

acetate

ophthalmic

suspension) 0.1 %

FOR TOPICAL OPHTHALMIC

USE

2.5mL

Sterile

PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle CartonPRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Carton

PRINCIPAL DISPLAY PANEL - 5 mL Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

5 mL5 mLeyevance ™

pharmaceuticals

Flarex ®

(fluorometholone

acetate

ophthalmic

suspension) 0.1 %

FOR TOPICAL OPHTHALMIC

USE

5 mL

Sterile

PRINCIPAL DISPLAY PANEL - 5 mL Bottle CartonPRINCIPAL DISPLAY PANEL - 5 mL Bottle Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1249631Flarex 0.1 % Ophthalmic SuspensionPSN7
1249629fluorometholone acetate 0.1 % Ophthalmic SuspensionPSN7
1249631fluorometholone acetate 1 MG/ML Ophthalmic Suspension [Flarex]SBD7
1249629fluorometholone acetate 1 MG/ML Ophthalmic SuspensionSCD7
1249631Flarex 0.1 % Ophthalmic SuspensionSY7
1249631Flarex 1 MG/ML Ophthalmic SuspensionSY7
1249629fluorometholone acetate 0.1 % Ophthalmic SuspensionSY7

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
FLUOROMETHOLONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
c643e98c-5dd1-707b-ab13-ba8a33389ab5Product name220250107
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
61e7d0c4-a2cb-3453-1dbf-f036c240eae7Product name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8ad2c55d-f8c3-a60f-1dff-eb2b216dc767Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
e516fbca-d3ac-e281-609f-a30f67b308edProduct name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
71776-100-03Flarex1 in 1 CARTONSUSPENSION/ DROPS17
71776-100-03Flarex2.5 mL in 1 BOTTLE, PLASTICSUSPENSION/ DROPS2.57
71776-100-05Flarex5 mL in 1 BOTTLE, PLASTICSUSPENSION/ DROPS57
71776-100-05Flarex1 in 1 CARTONSUSPENSION/ DROPS17

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
71776-100FLAREX (FLUOROMETHOLONE ACETATE) SUSPENSION/ DROPS [EYEVANCE PHARMACEUTICALS]7Current NDC, Legacy NDC, 4 package rows20250119_19918ea5-8568-44d6-b8ee-7b2197cee85c.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
71776-100-05ML - Milliliter71776-100e23d9b96-2afc-4e35-aec7-59980137bd3b12020-07-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71776-10071776-100-05, 71776-100-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML · Source PDF

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N019079-001FLAREXFLUOROMETHOLONE ACETATE0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-1184e616aacf4f…
2026-08-18 06:07:402026-07N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-1103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-112680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-115bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-1179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-111e350fbaab3a…
2024-05-31 18:47 UTC2024-05N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-118072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-115c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-115d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-114b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-1174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-1187673890dc5c…
2021-03-12 10:30 UTC2021-03N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-115aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-118869cabd3fbd…
2020-11-12 02:37 UTC2020-11N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11c0c555d07b60…
2019-12-14 00:12 UTC2019-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-113f01610625f2…
2019-09-15 20:21 UTC2019-09N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11b00525d2431f…
2019-07-19 19:46 UTC2019-07N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-116a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-111c564ffb4f44…
2023-12-20 04:57 UTC2023-12N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-119b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-113f0d92c62455…
2023-05-13 08:27 UTC2023-05N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11053a50430f4f…
2023-01-26 05:58 UTC2023-01N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-113bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-113a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N019079-001FLAREX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS1986-02-11f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FlarexFLUOROMETHOLONE ACETATEEyevance Pharmaceuticals19918ea5-8568-44d6-b8ee-7b2197cee85c2025-01-17Warnings, Adverse reactionsExact identifier
ndc (package): 71776-100-05
ndc (package): 71776-100-03
ndc (product): 71776-100
ndc11 (package): 71776010003
ndc11 (package): 71776010005
spl id: 2bed0334-e39e-c18b-e063-6294a90af598
spl set id: 19918ea5-8568-44d6-b8ee-7b2197cee85c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.